Myllia Biotechnology's CSO Tilmann Buerckstuemmer presented a CRISPR screen approach that maps regulators of NF-κB nuclear translocation in human cells, as showcased in a recent GEN webinar. The method enables systematic characterization of signaling pathways relevant to inflammation and disease.
The study uses pooled CRISPR libraries alongside cell painting readouts, tracking NF-κB translocation as a functional endpoint. This high-dimensional readout preserves spatial and temporal information, offering more mechanistic insight than conventional pooled screens.
No specific clinical or regulatory timeline was disclosed. The approach is positioned as a platform for target discovery in inflammatory and immune conditions, rather than a specific therapeutic program.
Myllia Biotechnology, a privately held firm, has not disclosed valuation or funding rounds tied to this platform. The competitive landscape includes other CRISPR screening firms like Synthego and Horizon Discovery, but Myllia's emphasis on cell painting adds a unique high-content dimension.
The method remains at the preclinical validation stage. Clinical translation would require further optimization and independent replication before entering regulatory pathways.
Despite the technical novelty, the absence of concrete drug candidates or human trial data limits immediate therapeutic impact. The platform's utility hinges on future partnerships or internal pipelines.